Key Insights

Highlights

Success Rate

60% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 60/100

Termination Rate

16.7%

4 terminated out of 24 trials

Success Rate

60.0%

-26.5% vs benchmark

Late-Stage Pipeline

4%

1 trials in Phase 3/4

Results Transparency

83%

5 of 6 completed with results

Key Signals

5 with results60% success

Data Visualizations

Phase Distribution

20Total
Not Applicable (7)
Early P 1 (1)
P 1 (3)
P 2 (8)
P 3 (1)

Trial Status

Recruiting6
Active Not Recruiting6
Completed6
Terminated4
Withdrawn2

Trial Success Rate

60.0%

Benchmark: 86.5%

Based on 6 completed trials

Clinical Trials (24)

Showing 20 of 20 trials
NCT04430725Active Not Recruiting

Microwave Ablation or Wedge Resection for the Treatment of Lung, Sarcoma and Colorectal Lesions, ALLUME Study

NCT04183218Completed

Characterizing Chemo-Radiotherapy Treatment-Related Cardiac Changes

NCT03634241Phase 2Completed

Pembrolizumab in Preventing Lung Cancer in Patients With Stage I-II Non-Small Cell Lung Cancer or High-Risk Pulmonary Nodules, the IMPRINT-Lung Study

NCT03110978Phase 2Active Not Recruiting

Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer

NCT04789681Phase 2Recruiting

Canakinumab for the Prevention of Lung Cancer, the Can-Prevent-Lung Trial

NCT03731585Not ApplicableActive Not Recruiting

Online Psychosocial Intervention in Improving Social Well-Being and Support in Women With Stage I-IV Non-small Cell Lung Cancer Undergoing Treatment

NCT03948100Not ApplicableRecruiting

Dyadic Yoga Intervention in Improving Physical Performance and Quality of Life in Patients With Stage I-IV Non-small Cell Lung or Esophageal Cancer Undergoing Radiotherapy and Their Caregivers

NCT03939481Active Not Recruiting

Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With Cancer

NCT04298606Early Phase 1Completed

A Vaccine (CIMAvax-EGF) for the Prevention of Lung Cancer Development or Recurrence

NCT04505267Phase 1Active Not Recruiting

NBTXR3 and Radiation Therapy for the Treatment of Inoperable Recurrent Non-small Cell Lung Cancer

NCT03819296Phase 1Recruiting

Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer

NCT04428905Phase 3Active Not Recruiting

Self-Management Survivorship Care in Stage I-III Non-small Cell Lung Cancer or Colorectal Cancer

NCT06918132Phase 2Recruiting

Cemiplimab and Fianlimab Before Surgery for the Treatment of Stage IB-IIIB Non-Small Cell Lung Cancer

NCT05292521Not ApplicableRecruiting

Quality of Life Intervention to Inform Patient Decision-Making in Early-Stage Lung Cancer

NCT04067830Phase 2Recruiting

Respiratory Muscle Training Before Surgery in Preventing Lung Complications in Patients With Stage I-IIIB Lung Cancer

NCT04348292Phase 1Terminated

Sirolimus and Durvalumab for the Treatment of Stage I-IIIA Non-small Cell Lung Cancer

NCT05412875Not ApplicableWithdrawn

Pilot Trial of E Cigarettes in Pts Diagnosed With Cancer of the Head, Neck, and Lung

NCT05213078Not ApplicableCompleted

Family Caregivers in Underserved Populations Providing Complex Cancer Care

NCT03995667Phase 2Terminated

Tumor Treating Fields (TTFields) Therapy to Manage Brain Metastases in Small Cell Lung Cancer

NCT04705025Not ApplicableTerminated

Cognitive-Behavioral Stress Management Device for the Treatment of Anxiety and Depressive Symptoms in Patients With Stage I-III Breast or Lung Cancer

Scroll to load more

Research Network

Activity Timeline